Market Overview

UPDATE: Morgan Stanley Reiterates On Mindray Medical International Ltd. On In-Line 1Q14 Sales Growth

Related MR
Top 4 Mid-Cap Stocks In The Medical Instruments & Supplies Industry With The Highest Profit Margin
Mindray Medical Misses Q4 Estimates; Stock Sells Off After-Hours

In a report published Tuesday, Morgan Stanley analyst Bin Li reiterated an Equal-Weight rating on Mindray Medical International Ltd. (NYSE: MR), but removed the $37.00 price target.

In the report, Morgan Stanley noted, “MR reported in-line 1Q14 sales growth on continued weak China business but stabilized ex-China growth, while non-GAAP profit was also in line. Notably, operating income was 13% below our estimate, but helped by the lower tax rate. Given the challenging China environment and the departure of the COO, Mr. Liu Jie, who has been instrumental to Mindray's healthy growth in the past few years, we do not expect improving profit growth in the near term.”

Mindray Medical International Ltd. closed on Monday at $33.67.

Latest Ratings for MR

Mar 2015Credit SuisseDowngradesNeutralUnderperform
Mar 2015JMP SecuritiesMaintainsMarket Underperform
Dec 2014Standpoint ResearchInitiates Coverage onBuy

View More Analyst Ratings for MR
View the Latest Analyst Ratings

Posted-In: Bin Li Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (MR)

Around the Web, We're Loving...